Immunosuppressant Medication Dosed Daily After Kidney Transplant

Status Terminated

Clinical Trial Summary

Medication non-adherence is a major risk factor for graft dysfunction and graft loss among pediatric and adult transplant recipients. Rates of non-adherence in these populations are estimated between 30 and 70%, with the highest prevalence in adolescent and young adult (AYA) transplant recipients. Treatment-related factors known to impact rates of adherence include the number of medication doses per day and the number of tablets or capsules a patient takes per day, or "pill burden". One approach to minimizing dosing frequency and pill-burden includes transitioning patients to once-daily formulations. The current literature investigating utilization of once-daily immunosuppressive regimens in the AYA kidney transplant population is limited.

Clinical Trial Description

One approach to minimizing dosing frequency and pill-burden includes transitioning patients to once-daily formulations.3 The current literature investigating utilization of once-daily immunosuppressive regimens in the AYA kidney transplant population is limited. Two studies have demonstrated safe and effective conversion of twice-daily tacrolimus to the Astagraf® in stable pediatric solid organ transplant recipients.4,5 Patients maintained equivalent tacrolimus exposure and experienced similar rates of rejection and graft loss in the first year post-conversion.5 To date, experience with another once-daily extended release (XR) tacrolimus product, Envarsus XR®, has not been published in the AYA population. Additionally, adherence studies evaluating a once-daily immunosuppression regimen including extended-release tacrolimus and azathioprine (which is dosed once daily as opposed to the twice daily dosing required for azathioprine's alternative mycophenolate mofetil) have not been conducted. Of note, and even though twice-daily mycophenolate has been shown to be superior to once-daily azathioprine early post-transplant, more long-term data suggest that this advantage may not persist.6 Furthermore, a recent Cochrane review addressed the question of mycophenolate versus azathioprine as primary anti-proliferative immunosuppression for kidney transplant recipients; it concluded that "balancing the benefits and harms of the two drugs remains a major task of the transplant physician to decide which agent" is appropriate for the individual patient. 7 Moreover, once-daily immunosuppression with tacrolimus extended-release and once-daily azathioprine has been used with excellent results at a British center that focusses on AYA kidney transplant recipients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04156204
Study type	Interventional
Source	University of Colorado, Denver
Contact
Status	Terminated
Phase	Early Phase 1
Start date	November 20, 2019
Completion date	November 27, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04709640` - Pilot Study to Improve Medication Management in Older Adults	N/A
Completed	`NCT03257579` - Myocardial Infarction Prescription Duration Adherence Study	N/A
Completed	`NCT05376397` - Testing THRIVE 365 for Black Sexual Minority Men (On The Daily)	N/A
Withdrawn	`NCT03427008` - A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients	N/A
Completed	`NCT03805451` - Life Steps for PrEP for Youth	N/A
Withdrawn	`NCT03292393` - Social Norms and Antihypertensive Medication Adherence	N/A
Completed	`NCT02914730` - Insulin Dosing Practices in Persons With Diabetes on Multiple Daily Injections
Completed	`NCT02823795` - The Supporting Patient Activation in Transition to Home Intervention	N/A
Not yet recruiting	`NCT02876848` - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)	N/A
Completed	`NCT02066935` - Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil Multicenter Study
Completed	`NCT02797262` - Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System	N/A
Completed	`NCT01934608` - The Effect of Synching Prescription Refills on Adherence	N/A
Completed	`NCT01770314` - Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.	Phase 2
Completed	`NCT01741311` - Secondary HIV Prevention and Adherence Among HIV-infected Drug Users	N/A
Recruiting	`NCT01105104` - An Enhanced Medication Monitoring Program	Phase 1
Withdrawn	`NCT01430702` - Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults	N/A
Completed	`NCT01859273` - Adherence Enhancement for Renal Transplant Patients	N/A
Completed	`NCT01118208` - Blister Packaging Medication to Increase Treatment Adherence and Clinical Response	N/A
Completed	`NCT00848224` - Improving Adherence to Pharmacological Treatment	N/A
Recruiting	`NCT06034301` - Pill Bottle vs Reminder App	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.